U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838065) titled 'Rehabilitation Management for Patients with Multiple Myeloma' on Jan. 22.
Brief Summary: Multiple myeloma (MM) is the second most common blood cancer. Bone involvement is very common in these patients: it is estimated that between 80% and 90% will develop bone lesions during the course of the disease. This represents a potential risk of fragility and pain, significantly impacting the patient's functional status and therefore worsening their quality of life. [1] The presence of bone lesions also represents a risk for the development of Skeletal-Related Events (SREs), which can include: pathological fractures, vertebral compression th...